cycloSal-Pronucleotides of 2‘-Fluoro-ara- and 2‘-Fluoro-ribo-2‘,3‘- dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
- 9 April 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (9) , 1615-1624
- https://doi.org/10.1021/jm981097r
Abstract
Novel, lipophilic cycloSal triesters 4a−c and 5a−c were synthesized, respectively, from the ara- and ribo-configurated 2‘-fluorinated-2‘,3‘-dideoxyadenosines 2 and 3. The cycloSal phosphotriesters were used as tools to study the effects of the two different sugar pucker conformations induced by two opposite configurations of the fluorine substituent at C2‘ of the dideoxyribose moiety. F-ara-ddA (2) is known to be an active anti-HIV agent, whereas the ribo-analogue 3 is inactive. Hydrolysis studies with the triester precursors 4a−c and 5a−c showed selective formation of the monophosphates of 2 and 3. The lipophilicity of the triester prodrugs was considerably increased by the cycloSal mask with respect to ddA (1), F-ara-ddA (2), and F-ribo-ddA (3). Phosphotriesters 4 and 5 proved to be completely resistant to ADA and AMPDA deamination. In parallel experiments, ribo-nucleoside 3 showed a 50-fold faster deamination rate relative to the ara-analogue 2. Against HIV in CEM cells, the phosphotriesters 4 proved to be 10-fold more potent than the parent nucleoside 2. Furthermore, the prodrugs 4 were active against MSV-induced transformation of C3H/3T3 fibroblasts, while 2 was inactive. More interestingly, the ribo-configurated phosphotriesters 5, prepared from the inactive F-ribo-ddA (3), showed a level of anti-HIV activity that was even higher than that of F-ara-ddA (2). Our findings clearly prove that the application of the cycloSal-pronucleotide concept to F-ribo-ddA (3) overcomes a metabolic blockade in the formation of the corresponding monophosphate.Keywords
This publication has 24 references indexed in Scilit:
- Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV InfectionsJournal of Medicinal Chemistry, 1995
- Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivativesInternational Journal of Clinical Pharmacy, 1994
- Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosineBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992
- Metabolism in Human Leukocytes of Anti-HIV Dideoxypurine NucleosidesAnnals of the New York Academy of Sciences, 1990
- Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-DideoxyinosineClinical Infectious Diseases, 1990
- Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIVJournal of Medicinal Chemistry, 1990
- Biochemical genetic analysis of 2′,3′-dideoxyadenosine metabolism in human T lymphocytesBiochemical and Biophysical Research Communications, 1988
- Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacementJournal of Medicinal Chemistry, 1987
- Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDSScience, 1984
- Protonic charge densities and kinetic acidities of carbon acidsThe Journal of Organic Chemistry, 1981